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In Vivo Cross-Priming of MHC
Class I±Restricted Antigens
Requires the TAP Transporter
Alex Y. C. Huang, Allen T. Bruce, peptide transfer has been demonstrated (Bachmann et
al., 1995). In both models, ingested antigens never gainDrew M. Pardoll, and Hyam I. Levitsky
Department of Oncology direct access to the cytoplasm of the APCs. Alterna-
tively, the TAP-dependent pathway involves transfer ofThe Johns Hopkins University School of Medicine
Baltimore, Maryland 21205 antigens from the phagosome to the cytoplasm for pro-
cessing, followed by transport of resulting peptides into
the ER and binding to nascent MHC class I molecules
(Kovacsovics-Bankowski et al., 1993; Kovacsovics-Summary
Bankowski and Rock, 1995). This mechanism assumes
a pathway by which phagocytosed antigens can effi-Recent in vitro evidence suggests two alternative
ciently enter the cytoplasm from the phagosomal com-mechanisms by which bone marrow±derived APCs
partment. Such a pathway has been described pre-may process exogenous antigens for presentation to
viously for some intracellular pathogens (Brunt et al.,CTL in vivo, a phenomenon termed cross-priming. Al-
1990; Campbell, 1994).though in vitro studies have suggested that both TAP-
Using a bone marrow chimera system to study initia-dependent and TAP-independent pathways exist, we
tion of CTL responses in vivo, we demonstrate an abso-have now demonstrated an absolute requirement for
lute requirement for transport of antigenic peptides froma functional TAP for cross-priming to occur in vivo.
the cytoplasm to the ER, even when the antigen origi-Bone marrow chimeras reconstituted with marrow
nates from outside of the APCs. Mice with TAP-deficientfrom TAP-defective donors develop functional CD81
(TAP2/2) bone marrow±derived APCs are unable to initi-CTL, but have APCs with disrupted TAP function. In
ate CTL responses against exogenous antigens,such chimeras, in vivo priming of naive CTL was ob-
whereas mice with normal APC (TAP1/1) generate aserved when antigen was targeted to the ER in a TAP-
strong cross-priming activity in vivo. These results pro-independent fashion, but cross-priming could not be
vides definitive in vivo evidence that cross-priming uti-demonstrated. These results support the TAP-depen-
lizes a phagosome to cytoplasm TAP-dependent path-dent mechanism of cross-priming.
way for antigen processing.
Introduction
Results
Induction of cytotoxic T lymphocyte (CTL) responses
requires the processing of protein antigens into peptides Characterization of the TAP2/2 → F1 Bone
Marrow Chimerathat bind to major histocompatibility complex (MHC)
class I molecules (Townsend and Bodmer, 1989). In To study cross-priming phenomenon in vivo, we have
utilized a model system in which influenza virus nucleo-vitro, most cell types only present endogenously ex-
pressed antigens, utilizing the transporter associated protein (NP), which has distinct dominant H-2Kd and
H-2Db restricted epitopes, is expressed in immunizingwith antigen processing (TAP) to transport peptides gen-
erated in the cytoplasm into the endoplasmic reticulum tumor cells, CT26-NP. We have previously shown that
vaccination of parent → F1 chimeras (H-2b→H-2b3d), in(ER) (Bennink et al., 1993; Bijlmakers and Ploegh, 1993;
Deverson et al., 1990; Goldberg and Rock, 1992; Kelly which the MHC haplotype of bone marrow±derived cells
does not match the MHC haplotype of the tumor cellet al., 1992; Monaco et al., 1990; Rammensee et al.,
1993; Spies et al., 1992; Trowsdale et al., 1990; Yewdell (H-2d), generates CTL with exclusive specificity for NP
epitopes restricted to the MHC class I allele presentand Bennink, 1993). In contrast, CTL responses initiated
in vivo can also involve processing and presentation on the bone marrow±derived cells (Huang et al., 1994).
Because there is no detectable direct priming of CTLof exogenous antigens by host bone marrow±derived
antigen-presenting cells (APCs), a phenomenon termed by the tumor in this system, it is well suited to determine
whether or not cross-priming utilizes a TAP-dependentcross-priming (Bevan, 1976a, 1976b; Gooding and Ed-
wards, 1980; Huang et al., 1994). pathway.
Two parallel sets of bone marrow chimeric miceThe primary mechanism by which peptides derived
from exogenous antigens combine with MHC class I were constructed. Lethally irradiated (B6 3 BALB/c)F1
(H-2b3d) mice were rescued with bone marrow from eithermolecules is currently unresolved. In vitro experiments
with purified macrophage populations suggest alterna- wild-type H-2b mice (TAP1/1) or H-2b mice expressing a
disrupted TAP1 gene (TAP 2/2). The bone marrow chime-tive models that differ in their dependence on the TAP
transporter complex. In one model of the TAP-indepen- ras were tested 4 months later for complete graft recon-
stitution using flow cytometric analysis with haplotype-dent pathway, ingested antigens are processed in the
phagosome followed by regurgitation of the resulting specific anti-MHC class II antibodies (Huang et al., 1994;
data not shown). Peripheral T cells were also tested forpeptides, which bind to empty MHC class I molecules
on the surface of the same or neighboring cells (Harding the presence of both mature CD42CD81 and CD41CD82
T cell subsets (Figure 1a). While the TAP2/2 donor miceand Song, 1994; Pfeifer et al., 1993). More recently, a
TAP-independent pathway not involving extracellular have markedly reduced numbers of CD42CD81 T cells
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Figure 1. Characterization of TAP2/2 (H-2b) →
F1 (H-2b3d) Bone Marrow Chimera Mice
(a) Mature peripheral CD41CD82 and CD42
CD81 cells developed in the TAP2/2 bone mar-
row chimeras (upper left). As controls, splen-
ocytes from the TAP1/1 (H-2b) → F1 (H-2b3d)
chimera (upper right), the F1 (H-2b3d) → F1
(H-2b3d) chimeras (lower left), and the TAP2/2
(H-2b) donor mice were also analyzed. Per-
cent of cells was displayed in each of the four
quadrants. X axis: CD8±fluorescein isothiocy-
anate. Y axis: CD4±phycoerythrin.
(b) Mature splenic T cells in the TAP2/2 → F1
chimera mice (open triangle) developed and
responded functionally to minor histocom-
patibility antigens presented on the APCs
from the DBA/2 mice. BALB/c (open circle)
and TAP1/1 (H-2b) → F1 (H-2b3d) (open square)
mice also developed CTL responses against
ConA blasts from DBA/2 mice after immuni-
zation with DBA/2 splenocytes. As a negative
control, DBA/2 (closed circle) mice failed to
generate CTL against self-antigens when im-
munized with syngeneic APC.
(c) None of the immunized mice in (b) devel-
oped CTL activity against ConA blasts from
BALB/c mice. The experiments were re-
peated twice with similar results.
in the periphery, both TAP2/2 → F1 and TAP1/1 → F1 directly priming host T cells to minor antigens, enabling
an assessment of their function independent of the en-chimeras have normal numbers and ratios of peripheral
mature T cells similar to that of the control F1 → F1 dogenous APC function of the chimeras. Both TAP1/1
→ F1 and TAP2/2→ F1 bone marrow chimeras devel-mice. The presence of normal numbers of CD42CD81
T cells in the chimeras suggests that positive selection oped CTL responses against DBA/2 minor antigens that
were similar to those generated by BALB/c mice (Figureoccurs normally on the TAP1/1 thymic epithelium of the
recipient. 1b). The CTL responses were specific to the DBA/2
minor antigens, since no CTL activities can be detectedT cells from the TAP2/2 → F1 chimeric mice were next
characterized functionally for their ability to respond to against syngeneic BALB/c minor antigens (Figure 1c).
Thus, T cell development in the TAP2/2 → F1 chimeraminor histocompatibilityantigens in vivoafter immuniza-
tion with DBA/2 (H-2d) splenocytes. Professional APCs seemed to be both phenotypically and functionally simi-
lar to that seen in the control TAP1/1 → F1 chimera.in the immunizing splenocyte population are capable of
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square). The lack of NP-specific CTL persisted even
after a secondary boosting in vivo (Figure 2b, square).
NP-Specific CTL Can Be Primed in the
TAP2/2 → F1 Chimera Immunized with
Targeted Vaccinia Minigene Constructs
While these results suggest that in vivo cross-priming
is a TAP-dependent process, it is also possible that
the absent NP 366±374 1 Db response was due to a
repertoire defect within the CD8 T cell subset of the
TAP2/2 → F1 chimera related to abnormal T cell develop-
ment. Although their response to minor histocompatibil-
ity antigens appeared normal (see Figure 1b), subtle
repertoire perturbations might specifically affect CD8
responses to NP 366±374 1 Db. Another possibility is
that the APCs derived from TAP2/2 bone marrow pro-
genitors have a partial defect in providing costimulatory
signals to naive T cells.
To address these possibilities, we utilized a vaccine
approach that should introduce NP 366±374 peptide into
the ER of APCs through a TAP-independent pathway.
TAP2/2 → F1 chimeras were immunized with a recombi-
nant vaccinia virus expressing a minigene encoding NP
366±374 linked to a ER signal sequence (Vac±sig-NP
366±374) (Minev et al., 1994; Restifo et al., 1995). This
peptide can use the signal-recognition particle complex
to translocate to the ER followed by cleavage of the
signal sequence. Figure 3 shows that TAP2/2 → F1 chi-
meras generated strong NP 366±374 1 Db CTL re-
sponses after immunization with Vac±sig-NP 366±374
(circle) but not with Vac±NP 366±374 (which expresses
NP 366±374 without a signal sequence) (square) or
Vac±NP (encoding the full-length NP protein) (triangle),
whereas TAP1/1 → F1 chimeras developed NP 366±374
1 Db CTL responses to all three recombinant vaccinia
constructs. These results indicate that the TAP2/2 → F1
Figure 2. TAP2/2 → F1 Chimeras Fail to Generate H-2b-Restricted chimeras are perfectly capable of responding to this
NP-Specific CTL after Immunization with CT26-NP antigenic peptide, NP 366±374, as long as it can get into
Both TAP2/2 → F1 (open square) and TAP1/1 → F1 (open circle) the ER.
chimeras were immunized with irradiated CT26-NP either once (a) The TAP dependence of cross-priming seen in this
or twice 2 weeks apart (b). Splenocytes were analyzed in vitro for
chimera system may reflect inefficient exogenous load-the presence of NP-specific CTL by lysis against NP±peptide pulsed
ing of MHC class I molecules on TAP2/2 APCs comparedsurrogate (H-2b) target cells. Lysis of target cells pulsed with an
inappropriate peptide (NP 147±155) was less than 5%. with normal APCs. To address this possibility, we com-
pared the ability of TAP2/2 versus TAP1/1 splenocytes
to activate NP-specificCTLs in vitro. CTL from influenza-In Vivo Cross-Priming of NP-Specific CTL
primed mice were used to determine the NP peptideDoes Not Occur in the TAP2/2 → F1
dose response curve (Figure 4a). Subsequently, twoBone Marrow Chimera
subsaturating concentrations of NP peptide were usedThe TAP2/2 → F1 and TAP1/1 → F1 chimeras were next
to compare the relative efficiency of peptide loading forimmunized with irradiated colorectal tumor, CT26-NP
the two APC populations. An equivalent level of NP-(H-2d), expressing the influenza virus NP antigen (Figure
specific CTL activation was observed when stimulated2). As we found previously (Huang et al., 1994), cross-
by either TAP2/2 or TAP1/1 splenocytes pulsed with ei-priming occurred readily in the TAP1/1 → F1 mice, which
ther 1 mM (Figure 4b) or 10 mM (data not shown) NPdeveloped a strong NP-specific H-2Db-restricted CTL
366±374 peptide for as little as 5 min, suggesting thatresponse after one (Figure 2a, circle) or multiple rounds
differences in the ability to load MHC class I on two(Figure 2b, circle) of immunizations. None of the immu-
APC populations are not likely to account for the TAPnized chimeric mice developed a H-2Kd-restricted NP-
dependence of cross-priming seen in the chimeraspecific CTL response (data not shown), reconfirming
system.that the immunizing tumor cells, CT26-NP, cannot
directly prime naive CTL in vivo. In contrast with the
Discussioncross-priming demonstrated in the TAP1/1→F1 mice, no
NP-specific H-2Db-restricted CTL were detected in the
Taken together, our experiments support a TAP-depen-chimeras reconstituted with TAP2/2 bone marrow, re-
flecting an absence of cross-priming in vivo (Figure 2a, dent pathway for in vivocross-priming. As noted, in vitro
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Figure 3. TAP2/2 → F1 Chimeric Mice Have the Potential of Mount-
ing an NP-Specific H-2Db-Restricted CTL Response
(a) The chimeric mice were infected with recombinant vaccinia virus
Figure 4. TAP2/2 APCs Can Efficiently Capture and Present NP 366±encoding the whole NP protein (Vac±NP, open triangle), the mini-
374 to CTLs In Vitrogene encoding the nonameric NP 366±374 sequence (Vac±NP 366±
(a) Splenocytes from TAP2/2 and TAP1/1 mice were pulsed with374, open square), or the minigene downstream of an ER insertional
various concentrations of NP 366±374 peptide at 378C for 1 hr. Wesequence (Vac±sig-NP 366±374, open circle). Splenocytes from
analyzed 24 hour supernatants for GM-CSF after incubating thethese chimeras were analyzed for their ability to lyse a MC57G (H-2b)
peptide-pulsed splenocytes with CTLs specific for the NP 366±374pulsed with the synthetic NP 366±374 peptide.
peptide.(b) As a control, TAP1/1 → F1 chimeras were also infected with the
(b) TAP2/2 splenocytes were pulsed at 378C at various time intervalssame recombinant viruses. This experiment has been repeated three
with a subsaturating amount (1 mM, arrow in [a]) of NP 366±374times with similar results. Lysis of target cells pulsed with NP 147±
peptide (solid bars) or NP 147±155 peptide (hatched bars). As a155 was less than 5% in all cases.
comparison, TAP1/1 APCs were also pulsed with either NP 366±374
peptide (open bars) or NP 147±155 peptide (dotted bars). The pulsed
studies have yielded conflicting results that have led to APCs were washed after the indicated time interval and mixed with
NP 366±374-specific CTLs for 24 hr. The supernatants were assayedalternate models to account for how exogenous antigen
for GM-CSF in an ELISA asay.gains access to class I MHC. It has been proposed that
antigen can be regurgitated onto the APC surface from
the phagosome, delivered to a specialized endosomal
compartment where both class II and class I molecules conditions, it is difficult to predict which of these condi-
tions reflect those that exist in vivo. In spite of the alter-are loaded, or transported from the endosomal compart-
ment to the cytoplasmic space for further processing. nate routes of antigen trafficking demonstrated in vitro,
we have shown a strict dependence of in vivo cross-While these studies demonstrate that each of these
pathways may be operative under certain experimental priming on APCs with a functional TAP transporter.
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Several important factors are likely to influence cross- Listeria monocytogenes, which transfer from phago-
some to cytoplasm by secreting a chaotropic phago-priming in vivo, including the local antigen density, the
form in which antigen is encountered for processing, some destabilizing protein (Brunt et al., 1990; Campbell,
1994). In addition, recent morphological evidence in vitrothe migration of APCs to the appropriate lymphoid mi-
croenvironment, and the type(s) of APCs involved. Rock has shown that soluble proteins, such as ovalbumin,
can be taken up by bone marrow macrophages via mac-and colleagues (Kovacsovics-Bankowski and Rock,
1994; Rock et al., 1993) have argued that such a pathway ropinocytosis and gain access to the cytosol for conven-
tional MHC class I antigen processing pathway (Norburymay only be operative in a subset of phagocytic macro-
phages. In contrast, nonmacrophage APCs have re- et al., 1995).
Bevan and others (Bevan, 1987; Huang et al., 1994;cently been shown to have the capacity to process anti-
gens in this fashion in vitro (Reis e Sousa and Germain, Rock et al., 1993) have proposed that the necessity for
cross-priming stems from the requirement that bone1995). In the present study, the outcome is not biased
by assumptions relating to the relevant APC population marrow±derived APCs, which express appropriate co-
stimulatory molecules and migrate to the appropri-mediating cross-priming in vivo.
It could be argued that this model system lacks the ate lymphoid microenvironment, present MHC class
I±restricted antigens in order to initiate CD8 responses.sensitivity to detect exogenous peptide loading. We feel
this is unlikely due to the fact that splenocytes from Thus, if an antigen is expressed exclusively in non-APCs
(such as tumor antigens in an epithelial tumor or a virusTAP2/2 mice, just as with TAP2 cell lines, express very
low levels of peptide-filled MHC class I molecules (as with epithelial tropism), it must be transferred to a bone
marrow±derived cell for MHC class I processing. Recentmeasured by a conformation-dependent antibody). (Van
Kaer et al., 1992; data not shown). Despite their reduced evidence suggests that a specialized peptide-carrier,
gp96, may be capable of mediating such transfer (ArnoldMHC class I molecule expression at the cell surface,
TAP2 cells required 100-fold less peptide epitope than et al., 1995; Suto and Srivastava, 1995). However, how
such proteins deliver peptide antigens into the cyto-the wild-type cell to sensitize them for lysis by CTLs
(Cerundolo et al., 1990). Furthermore, we have shown plasm of the APCs is currently unknown. That the pro-
cess of cross-priming also requires TAP, as shown inthat when peptide was added to TAP2/2 APCs in vitro
at a concentration where no increase in the level of the current study, suggests that the immune system
processes all MHC class I antigens through a commonstable class I molecules was detected by flow cytome-
try, TAP2/2 APCs were still able to present peptides to final pathway.
CTLs. While the in vitro peptide loading experiments
were performed at 378C, and resulted in equivalent levels Experimental Procedures
of CTL activation by the two APC populations exposed
to peptide for as little as 5 min, we recognize that this Mice
F1 (BALB/c 3 B6, H-2d3b), TAP1/1 (B6, H-2b), BALB/c (H-2d), andexperiment cannot precisely mimick the conditions en-
DBA/2 (H-2d) mice were obtained from the National Institutes ofcountered in vivo, and cannot formally rule out a subtle
Health (Frederick, Maryland). The TAP2/2 (H-2b) donor mice werebias against exogenous loading. Nevertheless, we feel
gifts of Dr. L. Van Kaer (Nashville, Tennessee). The TAP2/2 donor
it is likely that, if the regurgitation pathway of MHC class mice were on a B6x.129 background.
I presentation were operative in vivo, TAP2/2 bone mar-
row±derived APCs should be capable of efficiently cap- Cell Line
turing and presenting the NP 366±374 epitope. The CT26-NP line was produced by infection of CT26, a colorectal
tumor line derived from BALB/c mice (H-2d), with a Moloney-basedWhile the TAP molecule was clearly involved in the
defective recombinant retrovirus containing both the NP gene fromprocessing of the exogenous NP antigens in our system,
the PR8 influenza strain and a neomycin-resistance gene, as de-it is certainly possible that the TAP-independent peptide
scribed previously (Huang et al., 1994). The expression of NP byregurgitation pathway defined by Pfeifer and colleagues
the CT26-NP was confirmed by intracellular staining with anti-NP
(Pfeifer et al., 1993) in vitro may be operative for some monoclonal antibody (MAb) (HB65) and by in vitro lysis by H-2Kd-
antigens in vivo. However, if peptides generated in the restricted NP-specific CTL.
phagosome do not perfectly fit the MHC class I±binding
groove, it is not clear that the cell membrane has the Construction of the Bone Marrow Chimeras
The TAP2/2 → F1, TAP1/1 → F1, and F1 → F1 bone marrow chimeraspeptide trimming apparatus that exists in the ER (Snyder
were constructed as described previously (Huang et al., 1994). Fromet al., 1994) to modify peptides for effective binding to
each of the constructs one mouse was sacrificed 4 months afterthe empty MHC class I molecules on the surface of the
the bone marrow reconstitution. Splenocytes were stained for MHC
APCs. class II molecules I-Ed and I-Ab with MAb 14.4.4 (IgG2a) and MAb
Because TAP localizes exclusively to the ER mem- Y-3P (IgG2a), respectively, to confirm complete reconstitution with
brane and transports peptides from the cytoplasm to donor bone marrow (data not shown). The splenocytes were also
stained with MAb 2.43 (anti-CD8) directly conjugated to fluoresceinthe ER (Kelly et al., 1992; Kleijmeeret al., 1992; Shepherd
isothiocyanate (X axis) and MAb GK1.5 (anti-CD4) conjugated toet al., 1993; Spies et al., 1992; Van Kaer et al., 1992),
phycoerythrin (Y axis) to access the relative levels of peripheralthe TAP dependence of cross-priming implies that
CD41 and CD81 T cell subtypes.phagocytosed antigens must somehow be released
from the phagosome into the cytoplasm. Transfer of
Immunization of Bone-Marrow Chimeras with Minor
phagocytosed antigens to the cytoplasm can either oc- Histocompatibility Antigens
cur via a specialized protein transporter or by disruption TAP2/2 → F1 chimera, TAP1/1 → F1 chimera, BALB/c, and DBA/2
of the phagosome. Precedent for the later mechanism mice were immunized with 1.5 3 107 live DBA/2 splenocytes intra-
peritoneally. The recipient mice were sacrificed 2 weeks later, andcan be found in certain intracellular bacteria, such as
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